Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by mmarquison Jun 14, 2011 2:10pm
244 Views
Post# 18713536

RE: UofC Honorary Degree holder attends Bilderberg

RE: UofC Honorary Degree holder attends Bilderbergeasymoney,

How is this pertinent to SSS? Sorry to be a bit thick, but your meaning in posting this isn't clear to me.

Are you implying that becasue Dr. Orbinski was at Bilderberg there were secret discussions among this world elite to ensure the survival of SSS and it's eventual success as a leading (non)-stem cell drug supplier; or were you simply trying to start a rumor that he and Heather were having a clandestine meeting with frank McKenna?

And please, anyone, correct me in my thinking but I've understood that SSS is not an embryonic-stem cell research company, so exactly what benefit is the stem cell protocol to us, except insofar as people constantly confuse us with an embryonic-stem cell firm.  Am I wrong on characterizing us in this way? Do we really do both types of research? Thanks.
 
You've picked my interest and I'd love to know your thoughts; Maybe you could provide a little more detail and explanation. 

M
Bullboard Posts